Exact Sciences to Present New Oncotype DX Genomic Prostate Score® Test Data and Exhibit its Full Urology Portfolio at the 2021 Virtual AUA Annual Meeting

New analysis of the SEER registry and the Oncotype DX® GPS™ assay highlights the test’s clinical utility in helping guide treatment decisions at the time of diagnosis

MADISON, Wis., September 2, 2021 – Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the company will present new data and exhibit its portfolio of prostate cancer genomic tests at its virtual booth, during the American Urological Association’s Annual (AUA 2021) Meeting, being held September 10-13. This is the first AUA meeting where Exact Sciences will feature its full Oncotype® portfolio of urology genomic assays, including the Oncotype DX Genomic Prostate Score® (GPS™) test for localized prostate cancer; the Oncotype MAP™ Pan-Cancer Tissue test for solid tumors, including advanced prostate cancer; and the Oncotype DX AR-V7 Nucleus Detect® test for metastatic castration-resistant prostate cancer. An analysis of the SEER registry presented at the meeting will reinforce the value of the Oncotype DX® GPS test in helping guide treatment decisions in clinically low-risk prostate cancer patients.

“With clinical outcomes data across 15 publications and in more than 5,000 men, the Oncotype DX GPS test is one of the most rigorously studied assays in localized prostate cancer. The data we’re presenting at AUA once again highlight its clinical utility in helping physicians and patients decide between active surveillance and definitive treatment,” said Rick Baehner, chief medical officer of Precision Oncology for Exact Sciences. “We’re also thrilled to showcase our entire prostate cancer portfolio, supporting early to late-stage patient care, while connecting with our collaborators in the urology and oncology community.”

Key AUA activities featuring the Oncotype portfolio during the meeting include:

Friday, September 10: Industry Theatre Symposia

Topic: Navigating Prostate Cancer with Oncotype Tests: Molecular Testing to Inform Treatment Decisions for Localized and Advanced Prostate Cancer 

Presenter: Scott B. Sellinger, MD 

President, Advanced Urology Institute of Florida

Time: 9:30 AM PT

Sunday, September 12: Urologic Society for American Veterans Presentation

Topic: The Genomic Prostate Score and Adverse Features at Time of Radical Prostatectomy: Implications for Presurgical Planning    

Presenter: Dr. Vipul Patel, MD

Director of the Global Robotics Institute, Professor of Urology, AdventHealth Celebration

Time: 11:10 AM PT

Monday, September 13: Poster Presentation

Title:Active surveillance or watchful waiting in clinically low-risk prostate cancer patients in the SEER database with and without an Oncotype DX Genomic Prostate Score Assay

Presenter: Scarlett Gomez, MPH, PhD

Professor, Department of Epidemiology and Biostatistics, University of California, San Francisco

Time: 10:30 AM - 11:45 AM PT

In addition, Exact Sciences is proud to support the Urology Care Foundation’s 8th Annual Advocacy Connections Program as part of the AUA Annual Meeting. The program provides opportunities for patient advocacy organizations to collaborate with each other and the AUA community on policy priorities that benefit patients. The program also offers patient advocacy groups the chance to showcase patient-centered resources, while encouraging interaction and dialogue about tactics that effectively promote patient advocacy agendas. 

For more information about Exact Sciences’ AUA events and programming, visit https://www.oncotypeiq.com/en-US/announcements/AUA

About the Oncotype Portfolio of Prostate Cancer Tests
The Oncotype portfolio of prostate cancer tests applies advanced genomic science to reveal the unique biology of a patient’s tumor in order to help optimize cancer treatment decisions. The Oncotype DX Genomic Prostate Score test is designed for men with low-, intermediate-, and high-risk localized prostate cancer to help guide treatment decisions at the time of diagnosis, and the Oncotype DX AR-V7 Nucleus Detect test helps determine which patients with metastatic castration-resistant prostate cancer (mCRPC) are resistant to androgen receptor (AR)-targeted therapies. Patients with advanced prostate cancer, who eventually progress on hormonal agents, may benefit from the Oncotype MAP Pan-Cancer Tissue test, which delivers answers comprehensive tumor profiling and identifies actionable genomic and proteomic alterations within 3-5 business days[1] to determine eligibility for targeted therapeutic options. To learn more about the Oncotype urology portfolio of tests, visit www.OncotypeIQ.com or www.MyProstateCancerTreatment.org.

About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard® and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

NOTE: Oncotype, Oncotype DX, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks of Genomic Health, Inc. Exact Sciences and Cologuard are trademarks of Exact Sciences Corporation.

Forward-Looking Statements
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. You should not place undue reliance on forward-looking statements. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.



Media Contact: Stephanie Spanos, sspanos@exactsciences.com, 608-556-4380

[1] Data on file. Turnaround time is based on qualified sample receipt.

Subscribe To The Blog